Body mass index and incidence of Parkinson’s disease in French women from the E3N cohort study
Objective: We examined the association between BMI and PD incidence in women from the E3N cohort with repeated BMI measures over 29 years of follow-up,…PERCEPTION OF INDIVIDUALS WITH PARKINSON´S DISEASE ABOUT ISOLATION DURING THE COVID-19 PANDEMIC
Objective: To explore the knowledge of individuals with PD about COVID-19's world pandemic, and to investigate their perception about its impacts and consequences. Background: The…Advocacy for Neuropalliative Care in Parkinson Disease Care: The Need for an International Neuropalliative Care Society (INPCS)
Objective: To describe the International Neuropalliative Care Society (INPCS), its mission and values, and highlight the importance of palliative care for persons with movement disorders.…Non-motor symptoms in Parkinson’s disease
Objective: The objective of our study is to assess the prevalence of non motor signs in patients with parkinson’s disease and to propose an adapted…The Effects of Telepractice- Based LSVT-BIG Training in Patients with Parkinson’s Disease in Covid-19 pandemic: Preliminary Results
Objective: To investigate the effects of telepractice-based LSVT-BIG training on balance and mobility parameters in patients with Parkinson’s Disease (PD). Background: Patients with PD who…PHYSICAL ACTIVITY AT HOME IS ABLE TO REDUCE THE WORSENING IN QUALITY OF LIFE IN PARKINSON’S DISEASE DURING COVID-19 PANDEMIC
Objective: To compare the effects of physical activity (PA) at home with and without remote supervision on the motor and non-motor aspects of daily life…Safety and Tolerability of a Ketone Supplement in Parkinson’s Disease
Objective: To investigate the safety and tolerability of a high-dose exogenous ketone supplement in people with Parkinson’s Disease (PD). Background: Animal models and small pilot…The GlyT1 inhibitor bitopertin reduces in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with bitopertin on dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s disease (PD).…OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.
Objective: To validate the OPTIMIPARK questionnaire as a tool to help the clinician in the adjustment of dopaminergic treatment in Parkinson´s disease(PD). Background: At early…Opicapone in clinical practice in Parkinson’s disease patients with motor fluctuations and complications of therapy at baseline: findings from the OPTIPARK study
Objective: This post-hoc analysis evaluated the effects of opicapone (OPC) treatment in patients with Parkinson’s disease (PD) who experience motor fluctuations and complications of therapy…
- « Previous Page
- 1
- …
- 320
- 321
- 322
- 323
- 324
- …
- 338
- Next Page »